Impact Biomedical (IBO) Return on Sales (2022 - 2026)

Impact Biomedical's (IBO) quarterly Return on Sales came in at 3.26% in Q1 2026, down 298.18% on a QoQ basis from 0.82% in Q3 2025.

Impact Biomedical (IBO) Return on Sales (2022 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 3 years of Return on Sales data on file, last reported at 3.26% in Q1 2026.

Quarterly Return on Sales changed N/A year-over-year to 3.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.66% (changed N/A YoY) and the FY2022 annual result came in at 1.45%, changed N/A from the prior year.
Return on Sales retreated to 3.26% in Q1 2026, from 0.82% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.16% in Q2 2022 to a low of 20.5% in Q2 2025.
A 3-year average of 6.19% and a median of 2.04% in 2025 frame the typical range for Return on Sales.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	0.00%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	Impact Biomedical	49.45 Mn	49.44 Mn	2,000.00	-2.33%

Download Data